General Hospital Psychiatry
Volume 32, Issue 4 , Pages 360-367 , July 2010

Guideline-concordant antidepressant use among patients with major depressive disorder

  • Shih-Yin Chen, Ph.D.

      Affiliations

    • Abt Bio-Pharma Solutions, Inc., Lexington, MA 02421, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 781 372 6516; fax: +1 781 372 6681.
    • ,
  • Richard A. Hansen, Ph.D.

      Affiliations

    • Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill Chapel Hill, NC 27599, USA
    • ,
  • Bradley N. Gaynes, M.D., M.P.H.

      Affiliations

    • Department of Psychiatry, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    • ,
  • Joel F. Farley, Ph.D.

      Affiliations

    • Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill Chapel Hill, NC 27599, USA
    • ,
  • Joseph P. Morrissey, Ph.D.

      Affiliations

    • Department of Psychiatry, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    • Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    • Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    • ,
  • Matthew L. Maciejewski, Ph.D.

      Affiliations

    • Center for Health Services Research in Primary Care, Durham Veterans Affairs Medical Center, Durham, NC 27705, USA
    • Division of General Internal Medicine, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA

Received 20 December 2009 ,Accepted 15 March 2010.

References 

  1. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095–3105
  2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet. 1997;349:1498–1504
  3. Sclar DA, Robison LM, Skaer TL. Ethnicity/race and the diagnosis of depression and use of antidepressants by adults in the United States. Int Clin Psychopharmacol. 2008;23:106–109
  4. Practice guideline for the treatment of patients with major depressive disorder. 2nd ed. American Psychiatric Association; 2000;
  5. Depression in primary care: volume 2: treatment of major Depression. Clinical Practice Guideline No. 5. Rockville (MD): Dept of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research; Depression Guideline Panel; 1993;Available at: http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=hsarchive&part=A15593. Accessed April 11, 2010.
  6. Akincigil A, Bowblis JR, Levin C, Walkup J, Jan S, Crystal S. Adherence to antidepressant treatment among privately insured patients diagnosed with depression. Med Care. 2007;45:363–369
  7. Charbonneau A, Rosen AK, Ash AS, Owen RR, Kader B, Spiro A, et al. Measuring the quality of depression care in a large integrated health system. Med Care. 2003;41:669–680
  8. Jones LE, Turvey C, Carney-Doebbeling C. Inadequate follow-up care for depression and its impact on antidepressant treatment duration among veterans with and without diabetes mellitus in the Veterans Health Administration. Gen Hosp Psychiatry. 2006;28:465–474
  9. Olfson M, Marcus SC, Tedeschi M, Wan GJ. Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry. 2006;163:101–108
  10. Robinson RL, Long SR, Chang S, Able S, Baser O, Obenchain RL, et al. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims. J Manag Care Pharm. 2006;12:43–54
  11. Simon GE, Von Korff M, Rutter CM, Peterson DA. Treatment process and outcomes for managed care patients receiving new antidepressant prescriptions from psychiatrists and primary care physicians. Arch Gen Psychiatry. 2001;58:395–401
  12. Young AS, Klap R, Sherbourne CD, Wells KB. The quality of care for depressive and anxiety disorders in the United States. Arch Gen Psychiatry. 2001;58:55–61
  13. Fairman KA, Drevets WC, Kreisman JJ, Teitelbaum F. Course of antidepressant treatment drug type, and prescriber's specialty. Psychiatr Serv. 1998;49:1180–1186
  14. Hylan TR, Crown WH, Meneades L, Heiligenstein JH, Melfi CA, Croghan TW, et al. SSRI antidepressant drug use patterns in the naturalistic setting: a multivariate analysis. Med Care. 1999;37:AS36–AS44
  15. Weilburg JB, O'Leary KM, Meigs JB, Hennen J, Stafford RS. Evaluation of the adequacy of outpatient antidepressant treatment. Psychiatr Serv. 2003;54:1233–1239
  16. Bambauer KZ, Soumerai SB, Adams AS, Zhang F, Ross-Degnan D. Provider and patient characteristics associated with antidepressant nonadherence: the impact of provider specialty. J Clin Psychiatry. 2007;68:867–873
  17. Busch SH, Leslie D, Rosenheck R. Measuring quality of pharmacotherapy for depression in a national health care system. Med Care. 2004;42:532–542
  18. Chen S, Hansen RA, Farley JF, Gaynes BN, Morrissey JP, Maciejewski ML. Follow-up visits by provider specialty for patients with major depressive disorder initiating antidepressant treatment. Psychiatr Serv. 2010;61:81–85
  19. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915–920
  20. Williams JW, Mulrow CD, Chiquette E, Noel PH, Aguilar C, Cornell J. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med. 2000;132:743–756
  21. Reports of suicidality in pediatric patients being treated with antidepressant medications for major depressive disorder (MDD), Vol. 2008, Food and Drug Administration Public Health Advisory, 2003. Available at: http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm168828.htm. Accessed April 11, 2010.
  22. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15:565–574
  23. Sclar DA, Robison LM, Skaer TL, Legg RF, Nemec NL, Galin RS, et al. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization. Clin Ther. 1994;16:715–730[discussion 74]
  24. Sclar DA, Skaer TL, Chin A, Okamoto MP, Gill MA. Utility of a transdermal delivery system for antihypertensive therapy: Part 1. Am J Med. 1991;91:50S–56S
  25. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care. 2005;11:449–457
  26. Sheehan DV, Eaddy MT, Shah MB, Mauch RP. Differences in total medical costs across the SSRIs for the treatment of depression and anxiety. Am J Manag Care. 2005;11:S354–S361
  27. Thompson D, Buesching D, Gregor KJ, Oster G. Patterns of antidepressant use and their relation to cost of care. Am J Manag Care. 1996;1239–1246
  28. Cantrell CR, Eaddy MT, Shah MB, Regan TS, Sokol MC. Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes. Med Care. 2006;44:300–303
  29. Stein MB, Cantrell CR, Sokol MC, Eaddy MT, Shah MB. Antidepressant adherence and medical resource use among managed care patients with anxiety disorders. Psychiatr Serv. 2006;57:673–680
  30. HEDIS 2006. Healthcare Effectiveness Data & Information Set. Vol. 2, Technical Specifications. Washington (DC): National Committee for Quality Assurance (NCQA); 2005;
  31. Chen, X., Ender, P., Mitchell, M. and Wells, C. (2003). Regression with Stata. Available at http://www.ats.ucla.edu/stat/stata/webbooks/reg/default.htm. Accessed on August 5, 2008.
  32. Clark DO, Von Korff M, Saunders K, Baluch WM, Simon GE. A chronic disease score with empirically derived weights. Medical Care. 1995;33:783–795
  33. Parsons LS. In: Reducing bias in a propensity score matched pair sample using greedy matching techniques in SAS Users Group International (SUGI) Conference 29, Montreal, Canada. 2001;p. 214–226Available at: http://www2.sas.com/proceedings/sugi26/p214-26.pdf.
  34. Ai C, Norton EC. Interaction terms in logit and probit models. Economics letters. 2003;80:123–129
  35. Norton EC, Wang H, Ai C. Computing interaction effects and standard errors in logit and probit models. Stata J. 2004;4:154–167
  36. Wells KB, Burnam MA, Camp P. Severity of depression in prepaid and fee-for-service general medical and mental health specialty practices. Med Care. 1995;33:350–364
  37. Trivedi MH, Lin EH, Katon WJ. Consensus recommendations for improving adherence, self-management, and outcomes in patients with depression. CNS Spectr. 2007;12:1–27
  38. Gensichen J, Beyer M, Muth C, Gerlach FM, Von Korff M, Ormel J. Case management to improve major depression in primary health care: a systematic review. Psychol Med. 2006;36:7–14
  39. Vergouwen AC, Bakker A, Katon WJ, Verheij TJ, Koerselman F. Improving adherence to antidepressants: a systematic review of interventions. J Clin Psychiatry. 2003;64:1415–1420
  40. Gilbody S, Whitty P, Grimshaw J, Thomas R. Educational and organizational interventions to improve the management of depression in primary care: a systematic review. JAMA. 2003;289:3145–3151
  41. Lin EH, Von Korff M, Katon W, Bush T, Simon GE, Walker E, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care. 1995;33:67–74
  42. Williams JW, Gerrity M, Holsinger T, Dobscha S, Gaynes B, Dietrich A. Systematic review of multifaceted interventions to improve depression care. Gen Hosp Psychiatry. 2007;29:91–116
  43. Gaynes BN, Rush AJ, Trivedi MH, Wisniewski SR, Balasubramani GK, McGrath PJ, et al. Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR⁎D. J Gen Intern Med. 2008;23:551–560

☆ Conflict of interest statement: Dr. Hansen is supported by grant KL2RR025746 from the National Center for Research Resources. A portion of this work was funded by the American Association of Colleges of Pharmacy New Investigator Program (NIP). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources, the National Institutes of Health or the American Association of Colleges of Pharmacy. Dr. Chen is employed by Abt Bio-Pharma Solutions. Dr. Hansen has received consulting fees from Takeda Pharmaceuticals. Dr. Farley has received grant funding from the Pfizer Foundation and consulting fees from Takeda Pharmaceuticals. Dr. Gaynes has received grants and research support from M-3 Information, Bristol-Myers Squibb Company and Novartis, and he has served as an advisor for Bristol-Myers Squibb Company. The other authors report no competing interests.

PII: S0163-8343(10)00057-5

doi: 10.1016/j.genhosppsych.2010.03.007

General Hospital Psychiatry
Volume 32, Issue 4 , Pages 360-367 , July 2010

Article Tools

* Image Usage & Resolution